Oxaloacetate CFS: Anhydrous Enol-Oxaloacetate Treatment of ME/CFS

Alan Cash presented an efficacy study by his company Terra Biological LLC on oxaloacetate in ME/CFS and Long COVID. Oxaloacetate is an important metabolite particularly for the citric acid cycle and glucose production. Reduced oxaloacetate concentrations have been demonstrated in ME/CFS. Taking the tautomeric enol oxaloacetate (AEO) is said to reduce the chronic inflammatory response, support the formation of new mitochondria, and promote the uptake of glucose into cells. In a pilot study, 76 ME/CFS patients showed an average 33% reduction in fatigue after 6 weeks. In a randomised controlled trial with 64 ME/CFS patients, which included rice flour as a placebo in the control group, the intervention group showed a 25–35% improvement in fatigue, and crashes occurred less frequently. 40% of people in the intervention group responded particularly strongly to the treatment, with their fatigue reduced by 63%. Another clinical trial with Long COVID patients showed an improvement in neurocognitive symptoms (reduced brain fog).